The 2026 Peptide Law Playbook
The plain-English guide to the largest U.S. peptide regulatory shift in a decade. Written for patients, practitioners, and anyone trying to navigate the post-April-15 landscape without falling into either the gray-market trap or the hype.
What's inside
- Part 1 — The April 15 reclassification in plain English. What the FDA did. What it changed. What it didn't.
- Part 2 — Compound by compound. Decision guide for all 12 reclassified peptides — research base, indications, what to ask a prescriber.
- Part 3 — The 10-point pharmacy checklist. The verification framework we apply to every pharmacy in the directory.
- Part 4 — State-by-state legal snapshot. Permissive / moderate / restrictive tiers, with the friction points called out.
- Part 5 — Goal-organized playbooks. Recovery, longevity, cognitive, skin, immune.
- Appendix. Glossary, primary-source citations, the prescriber conversation script.
What you get
- 60-page PDF (also ePub) delivered via Gumroad.
- Free post-PCAC update after the July 23–24 meeting (auto-delivered to buyers).
- Q4 2026 update including final 503A Bulks List placement.
- Lifetime access to subsequent revisions.
Refund policy
30-day no-questions refund through Gumroad. If the playbook isn't useful, you get your money back.
Educational content, not medical advice. © 2026 PeptidesBeat.